+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Oxford BioMedica Plc (OXB) - Financial and Strategic SWOT Analysis Review

1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Oxford BioMedica Plc (OXB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Oxford BioMedica Plc (Oxford Biomedica) is a biopharmaceutical company involved in the development and commercialization of gene-based medicines. It provides LentiVector, a sector leading lentiviral vector delivery platform. Based on this platform the company has developed a portfolio of gene and cell therapy product candidates in ophthalmology, oncology, central nervous system (CNS), and other therapy areas. It has partnership and license agreement with other companies to develop potential gene and cell therapy products. The company has presence in different locations in Oxfordshire, the UK. Oxford BioMedica is headquartered in Oxford, the UK.

Oxford BioMedica Plc Key Recent Developments

  • May 15, 2023: Oxford Biomedica launches TetraVecta - the next generation lentiviral vector system
  • Apr 26, 2023: Oxford Biomedica Appoints Leone Patterson as Non-Executive Director
  • Apr 26, 2023: Oxford Biomedica PLC Board Appointment
  • Apr 25, 2023: Oxford BioMedica : Preliminary results for the year ended 31 December 2022

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Oxford BioMedica Plc - Key Facts
  • Oxford BioMedica Plc - Key Employees
  • Oxford BioMedica Plc - Key Employee Biographies
  • Oxford BioMedica Plc - Major Products and Services
  • Oxford BioMedica Plc - History
  • Oxford BioMedica Plc - Company Statement
  • Oxford BioMedica Plc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Oxford BioMedica Plc - Business Description
  • Business Segment: Platform
  • Overview
  • Performance
  • Business Segment: Product
  • Overview
  • Performance
  • Geographical Segment: Europe
  • Performance
  • Geographical Segment: Rest of World
  • Performance
  • Geographical Segment: United Kingdom
  • Performance
  • Geographical Segment: United States
  • Performance
  • R&D Overview
  • Oxford BioMedica Plc - Corporate Strategy
  • Oxford BioMedica Plc - SWOT Analysis
  • SWOT Analysis - Overview
  • Oxford BioMedica Plc - Strengths
  • Oxford BioMedica Plc - Weaknesses
  • Oxford BioMedica Plc - Opportunities
  • Oxford BioMedica Plc - Threats
  • Oxford BioMedica Plc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Oxford BioMedica Plc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • May 15, 2023: Oxford Biomedica launches TetraVecta - the next generation lentiviral vector system
  • Apr 26, 2023: Oxford Biomedica Appoints Leone Patterson as Non-Executive Director
  • Apr 26, 2023: Oxford Biomedica PLC Board Appointment
  • Apr 25, 2023: Oxford BioMedica : Preliminary results for the year ended 31 December 2022
  • Apr 20, 2023: 2022 preliminary results revised date, guidance unchanged
  • Feb 20, 2023: Dr Frank Mathias to join Oxford Biomedica as new CEO on 27 March 2023
  • Feb 20, 2023: Oxford Biomedica PLC Dr Frank Mathias to join as new CEO on 27 March
  • Jan 27, 2023: Oxford Biomedica PLC Board Change
  • Dec 21, 2022: Oxford Biomedica to Present at 41st Annual J.P Morgan Healthcare Conference
  • Dec 14, 2022: Oxford Biomedica Solutions forms new partnerships with three biotechnology companies
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Oxford BioMedica Plc, Key Facts
  • Oxford BioMedica Plc, Key Employees
  • Oxford BioMedica Plc, Key Employee Biographies
  • Oxford BioMedica Plc, Major Products and Services
  • Oxford BioMedica Plc, History
  • Oxford BioMedica Plc, Other Locations
  • Oxford BioMedica Plc, Subsidiaries
  • Oxford BioMedica Plc, Key Competitors
  • Oxford BioMedica Plc, Ratios based on current share price
  • Oxford BioMedica Plc, Annual Ratios
  • Oxford BioMedica Plc, Interim Ratios
  • Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Oxford BioMedica Plc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Oxford BioMedica Plc, Performance Chart (2018 - 2022)
  • Oxford BioMedica Plc, Ratio Charts
  • Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Proteome Sciences Plc
  • Phynova Group Ltd
  • Agenus Inc
  • Vernalis R&D Ltd
  • Alliance Pharma Plc
  • Summit Therapeutics Inc
  • Silence Therapeutics Plc
  • Almac Group Ltd
  • Transgene SA
  • Vernalis R&D Ltd
  • Alliance Pharma Plc
  • Summit Therapeutics Inc
  • Silence Therapeutics Plc
  • Almac Group Ltd
  • Phynova Group Ltd
  • Agenus Inc
  • Transgene SA
  • Proteome Sciences Plc